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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre    over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved antd has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Etiology, epidemiology and impact 
This monograph briefly describes Bluetongue (BT), an infectious, non-contagious vector borne disease affecting 
domestic and wild ruminants. Its causal agent, the Bluetongue virus (BTV) is a non-enveloped double stranded 
RNA, that belongs to the genus Orbivirus. The BTV is considerably diverse and to date 26 serotypes, likely 27, 
have been identified. There is marked genetic variation within the virus, as a consequence of both genetic shift 
and drift. The vector is an insect belonging to the genus Culicoides, which has a number of species that host and 
transmit the virus. Once infected with BTV, female midges remain persistently infected for the remainder of 
their lives. 
Bluetongue has a worldwide distribution governed by the distribution of the vector Culicoides spp., wherever 
the vector species thrives the virus can potentially exist and cause disease. The global distribution of BTV is 
limited to a band between approximately 50°N and 35°S; however, Culicoides midges, including known BTV- 
vector competent species, occur beyond this global range. Although transmission is mainly by midges, some BT 
strains can be transmitted between ruminants in close contact, but it is thought to be of little epidemiological 
importance. Serotypes 25 and 26 might be the exceptions, as they do not seem to replicate readily in some 
Culicoides vectors. 
Sheep tend to be the ruminant species that are most clinically affected by BT, but cattle, goats, buffaloes and a 
number of wild antelopes also contract the disease and may have mild to inapparent disease manifestation. 
Clinical cases of BT occur mainly in sheep, while subclinical infections seem to predominate in most other 
species. Clinical disease in cattle is rare except in herds infected by the BTV-8 serotype. Common clinical signs 
include fever, depression, serous to mucopurulent nasal discharge, which may crust around the nostrils, 
hyperemia of the muzzle, oral and nasal mucous membranes, conjunctive and coronary band of the hooves. The 
muzzle, periocular region and face often become edematous. The lips and tongue might be very swollen in some 
animals; the tongue is occasionally cyanotic in severe cases, and may protrude from the mouth. Pregnant ewes 
can abort or give birth to lambs that are stillborn or have central nervous system lesions, retinal lesions and 
skeletal malformations. Deaths are often the result of pulmonary edema in acute cases, or secondary bacterial 
complications when the course is more prolonged 
Morbidity is very variable. Virulence and therefore mortality varies with the strain of BT virus and also with the 
ruminant host species affected; with sheep it also depends on the breed infected. Morbidity rates in sheep 
range from <5% to 50-75% or higher, and reach its highest point when the virus is first introduced. The case 
fatality rate is typically <30%, but can reach 50-90% in highly susceptible populations. Once a virus has become 
endemic, morbidity may decrease to low levels (1-2%), with very few deaths. 
After recovery from natural infection, sheep have a solid, life-long immunity to the homologous serotype but 
only partial or no protection immunity against heterologous types. 
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The economic and social impacts of the disease, are varied. In recent decades they have been particularly 
important in Europe, not only for the cost of the disease in terms of mortality and decreased production, but 
also for the impact on the cattle industry due to trade barriers. In 2007, a BTV-8 outbreak in France was 
estimated to cost $1.4 billion. The USA losses in trade and associated testing of cattle for BTV status has been 
estimated at $130 million annually. As for the LVIF target 20 countries, the economic and socio impact of 
bluetongue are most felt in India and South Africa, but there is very limited information, and is difficult to make 
definitive statements due to concerns regarding differential diagnosis with common diseases in the area. 
 
Incidence / Prevalence 
The incidence and prevalence of BT in the target countries for the LVIF differs widely. In Asia, only India has 
reported BT outbreaks regularly to the OIE. Indonesia and Nepal last reported BT to the OIE in 2006, however 
there are recent publications with prevalence data from Nepal. In Africa, only South Africa has reported it 
regularly to the OIE. But there are recent publications with BT seroprevalence data from Ethiopia, Madagascar 
and Uganda. More details are given in Section 3. 
 
Diagnostics 
This monograph also briefly outlines a number of techniques used in detecting exposure of ruminants to the 
virus. Definitive diagnosis of BT is based on the detection of antibody using a serological assay, or of antigen, 
using a virological assay, or of specific nucleic acids using molecular techniques, RT-PCR and sequence analysis, 
or by virus isolation in cell culture. 
No specific treatment is available for BT. Treatment of BT-affected involves only nonspecific supportive and 
nursing care. The most effective way to control BTV is by employing measures that prevent the introduction of 
BTV to a susceptible herd. All efforts to control BTV are generally directed at preventing the ruminant species 
from contracting the disease, mainly through vaccination, and denying/reducing exposure of susceptible 
ruminants to the vector. 
 
Current vaccines for BT 
Currently, two types of bluetongue vaccines exist, the live (attenuated) and the inactivated (killed) vaccines. 
Both types of vaccines may be monovalent or polyvalent. Presently, they are all serotype specific, and there are 
no vaccines that allow the differentiation between vaccinated and infected animals (DIVA). 
Live attenuated vaccines can be highly effective. They generate protective immunity after a single inoculation 
and they have proven effective in preventing clinical BT disease. They have been successfully used in places such 
as South Africa. When multiple serotypes exist, the situation is more complicated as it requires multivalent 
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vaccines because protection from BTV vaccines is serotype specific. Unfortunately, multivalent vaccines have 
problems resulting from interference between virus strains, varying immunogenicity and growth rates between 
virus strains, as well as variations in the immune responses of individual animals. Concerns have also been raised 
about under-attenuation (impact may vary with the different breeds of sheep), potential depressed milk 
production in lactating sheep and abortion/embryonic death and teratogenesis. Other concerns include the 
possibility tat the vaccine virus will infect vectors and will be established in the environment. 
Some authorities prohibit the use of live attenuated vaccines against BTV. Nonetheless, live attenuated BT 
vaccines have wide usage in South Africa, Italy, Morocco, Spain and France, and to a smaller extent in the USA. 
To overcome some of the drawbacks of live vaccines, inactivated vaccines have been developed although their  
main disadvantage is poor immunogenicity, and they usually require repeated immunization. Other potential 
disadvantages include increased costs due to the large amount of antigen required, and there are some 
concerns over the reliability of inactivation for each vaccine batch. Inactivated vaccines are generally safe. 
 
Commercial manufacturing of BT vaccines 
Some of the multinational large pharmaceutical companies are producing the BT vaccine such as Merial, Zoetis 
and MSD. Their focus is the developed countries. In Africa, OBP produces a live vaccine, and in India, IIL has 
recently launched the Raksha-Blu, an inactivated pentavalent vaccine. 
 
Research and Potential new vaccines and the way forward 
Despite the major advances in the understanding and prevention against BTV in trials with new generation 
vaccines, a commercial recombinant vaccine against BT remains elusive. 
Many approaches have been followed in order to develop new generation vaccines. Promising results have been 
obtained with virus-like particles (VLP)s, some recombinant viral vector vaccines, and lately with the use of 
reverse genetics, replication deficient virus vaccines have been developed which are stable and safe. Details are 
included in Section 8. Some of these vaccines can be used as a mixture of serotypes, and can potentially protect 
for multiple serotypes. These vaccines need to be tested at large scale. It is important to consider that many of 
the new vaccines are aimed to the developed countries markets (for example, they are based on the strains 
prevalent in Europe) and that explains why big multinational pharmaceutical vaccines are already producing the 
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Etiology & Epidemiology 
 
Bluetongue (BT) is an infectious, non-contagious, vector-borne viral epizootic disease that affects domestic and 
wild ruminants including sheep, goats, cattle, South American camelids, buffalo, bison, North American elk, 
bighorn sheep, antelope and deer. BT was first identified at the end of the 18th century in South Africa following 
importation of wool sheep from Europe, and was originally referred to a “malaria catarrhal fever of sheep” or 
“epizootic malignant catarrhal fever of sheep”. 
The bluetongue virus (BTV) belongs to the family Reoviridae, genus Orbivirus, which consists of 20 known 
species including other orbiviruses of economic importance such as epizootic hemorrhagic disease virus (EHDV), 
African horse sickness virus and equine encephalosis virus. The BTV is considerably diverse and to date 26 
serotypes, likely 27, have been identified [1]. Bluetongue virus serotypes 25 to 27 have been identified only 
recently as infections of small ruminants in Europe and the Middle East, and serotype 25 (BTV‑25; also known as 
Toggenburg orbivirus) has yet to be isolated, although it has been sequenced [1]. 
Structurally, BTV is a non-enveloped double stranded RNA (dsRNA) virus consisting a triple-layered icosahedral 
capsid composed of 10 linear segments with a genome of approximately 19.2 kb. These segments encode 4 non-
structural proteins (NS1-NS4) and 7 structural proteins referred to as viral sub-core proteins (VP1-VP7). The 10 
double stranded linear segments together with the viral sub-core proteins VP1, VP4, and VP6 are enclosed in a 
double-layered protein shell, with an inner layer of VP3 and an outer layer of VP7 proteins. Two protein units, 
VP2 and VP5, consist the outer capsid and encapsidate the inner core (See Figure 1). The VP2 and VP5 proteins 
are the only BTV proteins with capacity to induce neutralizing antibodies with VP2 being the major protein 
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Figure 1: Representative scheme of BTV structural proteins and dsRNA segments. Source: Schwartz-Cornil 
et al., 2008 [3]. 
 
Bluetongue virus infects its insect and mammalian hosts in alternating cycles, which gives the virus the 
opportunity to genetically diversify. Consequently, there is marked genetic variation among field strains of BTV 
in historically endemic regions, even among viruses of the same serotype from the same region. The genetic 
diversity and heterogeneity of field strains of BTV arise as a consequence of both genetic shift and drift. 
Specifically, genetic shift occurs by reassortment of individual viral gene segments during infections of cells with 
more than one virus serotype or strain or by intragenic recombination. In contrast, individual genes evolve by 
genetic drift as a consequence of quasispecies (a swarm of genetic viral variants all related to a common 
consensus sequence) evolution and founder effect during alternating cycles of virus replication in insect and 
mammalian hosts. Importantly, however, there is currently some uncertainty about the genetic basis of 
virulence and other important biological characteristics of individual BTV strains, e.g. the potential role of 
quasispecies (population) diversity in determining these characteristics is not yet known [1]. 
The BTV is known to be inactivated by 50°C and 60°C within 3 hours and 15 minutes respectively and by ß- 
propiolactone; iodophores and phenolic compounds. The virus is easily damaged by exposure to pH below 6.0 
and above 8.0; and reported as very stable in the presence of proteins, noted to have survived in blood stored at 
20°C for years (Anonymous, 2011). 
Transmission 
BTV is mainly transmitted between its ruminant hosts by biting midges (flies) of the genus Culicoides in the 
family ceratopoginidae in the order Diptera (See Figure 2). To date, up to 1400 species of Culicoides are known, 
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although only 30 of these are competent BTV vectors [4]. Culicoides spp are small (<3 mm) blood-sucking insects 
that occur worldwide. These flies breed in a wide variety of semi-aquatic sites and those that cause veterinary 
disease prefer soil that is organically enriched with dung and which is found in close proximity with their 
ruminant hosts. The most competent BTV vectors are C. imicola (Africa, the Middle East, southeast Asia and 
parts of Southern Europe), C. sonorensis (North America) and C. brevitarsis (Australia). A comprehensive 
summary of major vector species for ruminants and their distribution is shown in Figure 3. Transmission of BTV 
is mainly through female Culicoides, which, like mosquitoes, require a blood meal for egg production. Culicoides 
have a wide range of hosts including birds, amphibians and mammals, although this monograph will focus on 
susceptible ruminants only. Occurrence of bluetongue tends to be seasonal as it largely corresponds with the 
distribution of the infecting Culicoides spp (see Figure 3), which also displays a seasonal pattern [5]. Evidence 
from cattle and sheep indicates that BTV can also be transmitted transplacentally although whether this route of 




Figure 2: The transmission cycle of bluetongue virus. Source: Purse et al, 2005 [8] 
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Figure 3: The worldwide distribution of Bluetongue virus (BTV) serotypes and the primary Culicoides vectors 
in different geographical regions denoting six predominant BTV episystems. Source: Tabachnick 2010. [9]. 
 
There is uncertainty regarding the exclusive role of Culicoides midges in the transmission of BTV-25 and BTV-26 
[1]. Vector-independent transmission of BTV clearly can occur, although its significance is largely unknown. The 
epidemiology of BTV-25 infection of goats in Europe appears to be different from that of the other serotypes 
(BTV 1 to 24) and may not involve Culicoides midges. Recent studies also suggest direct contact transmission of 
BTV-26, likely by aerosol, between livestock. 
 
Epidemiology 
Bluetongue has been observed in Africa, the Middle East, Asia, Australia, the Americas and recently in Europe 
(Figure 3). Upon ingestion of the BTV from a viraemic host, the extrinsic incubation period of BTV involves the 
entry of the virus into the Culicoides vector, dissemination through the haemocoel and subsequent infection of 
the salivary glands. The replication period in the insect’s salivary gland is 6–8 days and infected midges remain 
infective for their entire lives. 
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Temperature affects most stages of the Culicoides life cycle, including the survival of adults and larvae through 
the winter months (enhanced by high winter temperatures), recruitment to the adult population and activity 
rates of adult Culicoides. Most stages of the Culicoides life cycle are also affected by the availability of moisture. 
Breeding habitats are semi-aquatic; larvae and pupae require moist habitats and adults are prone to desiccation. 
The incubation period for bluetongue is typically 7 days although experimental inoculation has demonstrated a 
wider range of incubation of between 2 and 15 days. 
Although adult Culicoides are killed by cold temperatures, in temperate regions BTV infections do not persist 
beyond 60 days. One notable aspect of BTV is its ability to survive between two midge seasons in temperate 
climates. This phenomenon is called “overwintering” and the mechanisms by which this happens are not well 
understood [10]. More recently, researchers at the University of California, Davis have demonstrated that the BTV 
virus is able to replicate and survive in a proportion of long-lived female midges which survive winter [11]. 
Mortality, morbidity and virulence depend on the infecting BTV strain and ruminant host species. Typically, 
sheep, yak, llamas, and alpacas are most susceptible, while cattle and other wild ruminants display some 
resistance to disease, although are fully susceptible to infection [12]. Cattle are considered reservoirs of infection 
as they experience longer durations of viremia. Goats appear resistant to disease from BTV although conflicting 
reports in literature due to varying experimental conditions make it difficult to compare the data [6][13]. 
Susceptibility of sheep to BTV is determined by the breed, age and immune status of the animal. For instance, 
North European breeds are very susceptible, while African or South-East Asian breeds are less susceptible. BTV 
infects animals of all ages and sexes, but older animals experience more severe disease [14]. BTV infection is also 
more acute in susceptible lambs that have not previously been exposed or those with declining maternal 
antibodies, while animals with previous exposure or higher maternal antibodies display a favourable course of 
disease. This in part, could explain the occurrence of outbreaks when susceptible animal species are introduced 
into BTV is endemic areas or when BTV virulent strains enter previously unexposed ruminant populations [15]. 
 
In sheep and wild deer and antelopes, the mortality rate can reach 70% and 90% respectively. In recent 
outbreaks in Europe, the BTV serotype infected high numbers of cattle but mortality remained relatively low at 
1%. Following initial entry of BTV into a flock of sheep, between 50-70% may show clinical signs. In a number of 
European, Asian and South American ruminant species kept in European zoos, morbidity rates varied but 
reached up to 40%, depending on the species [5]. 
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In sheep, BT occurs in three forms: acute, chronic and subclinical. Following incubation, animals develop fever, 
apathy, laboured breath, nostril and lip hyperaemia and excessive saliva and serous nasal discharges. The nasal 
discharge is initially clear, but becomes mucopurulent and forms a crust around the nostrils after drying. The 
tongue, lips and sub-mandibulum develop oedema, petechial haemorrhage is observed on the conjunctiva and 
ulceration of the oral mucosa is seen. The tongue may swell and develop a purple colour (hence the name 
“bluetongue”) due to cyanosis, although this is not common. A proportion of animals may suffer from dyspnea, 
haemorrhagic diarrhoea or vomiting, resulting in aspiration pneumonia. At the end of the pyrexia stage, affected 
sheep may stand with an arched back and avoid movement due to coronitis, laminitis or paresis and necrosis of 
striated muscles. Affected sheep may also develop torticollis and dermatitis resulting in breaks in the wool. 
Pregnant ewes abort, the fetus may become mummified or ewes may give birth to lambs with congenital 
defects like hydrocephalus, cerebral cysts o retinal dysplasia. Sheep that are chronically infected may succumb 
to secondary infections such bacterial pneumonia [15]. 
 
Clinical disease in cattle is rare except in herds infected by the BTV-8 serotype [16]. Clinical signs typically 
resemble those of sheep and are largely thought to be a consequence of type I hypersensitivity mediated by IgE. 
The skin around teats becomes inflamed may crack and peel. Cattle display reduced milk production and during 
early pregnancy, embryos may die, undergo resorption, abort or if they survive, could be born with malformities 
[16][17]. Foetuses infected between 2 and 4 months of gestation develop serious central nervous system (CNS) 
defects while infections that occur few weeks before birth, could result in mild encephalitis. 
 
As mentioned above, goats are rarely infected with BTV, and do not typically display signs of clinical disease. 
However, those that do, display similar signs to those of sheep but with less severity. 
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Definitive diagnosis of BT is based on the detection of antibody using a serological assay, or of antigen, using a 
virological assay, or of specific nucleic acids using molecular techniques, RT-PCR and sequence analysis, or by 
virus isolation in cell culture. The main clinical pathology sample is blood for both serology and detection of the 
virus or viral antigen. 
 
OIE recognized tests: 
The techniques briefly highlighted in the Table below are the ones acknowledge by the OIE for diagnosis of 
bluetongue and the purpose for using them. Some more details are given on a number of the tests noted in 
Table 1. 
Table 1: Tests recommended by the OIE for BT (OIE Terrestrial Manual of Diagnostic tests and vaccines for 




Key: +++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or 
other factors severely limits its application; – = not appropriate for this purpose. 
Although not all of the tests listed as category +++ or ++ have undergone formal validation, their routine nature and 
the fact that they have been used widely without dubious results, makes them acceptable. 
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It is performed in embryonated chicken eggs, cell culture or sheep. BTV can be isolated from a variety of tissues 
including spleen, lung, bone marrow, liver, kidney, lymph node, tongue, thoracic fluid, semen, brain, mucosal 
epithelium, post mortem blood and urine, and from foetuses. Blood collected into EDTA or heparin tubes can be 
used for virus isolation and for extraction of viral RNA for molecular assays. Blood for virus detection should be 
collected while the animal is pyrexic, as this is the height of the viraemic period. Blood for virus isolation should 
be stored at 4 °C, not frozen. Sterile blood samples can be transported at room temperature for a few days and 
virus isolation should still be possible. Tissues obtained at necropsy can be stored in tissue culture medium 
containing antibiotics. This allows both virus isolation and PCR to be carried out on the samples. 
 
Immunological methods: 
These methods can be used to serogroup BT viruses by i) immunofluorescence and/or ii) antigen capture 
enzyme-linked immunosorbent assay and iii) immunospot test. 
Antigen detection ELISA can be used for the detection of BTV antigens. Polyclonal antibodies or serogroup- 
specific MAb adsorbed to the ELISA plate is used to capture virus-derived proteins from embryonated chicken 
eggs, cell culture, infected insects or sheep blood, and the bound antigen is then detected using a second 
antibody. 
Also immunological methods can be employed for serotyping by virus neutralisation via i) plaque reduction, ii) 
plaque inhibition, iii) microtitre neutralisation, and iv) fluorescence inhibition test 
• Virus neutralisation tests (VNTs) are used to serotype virus isolates. They are based on the inactivation 
of the infectivity of the test virus by standardised preparations of polyclonal neutralising antibodies to 
each of the known BTV serotypes. They depend on the antigenic specificity of VP2 and to a lesser extent 
VP5. Different types of VNT include the plaque reduction neutralization test, plaque inhibition test, 
microtitre neutralization test and fluorescence inhibition test. These assays can only be carried out if the 
laboratory has high-quality standardised antisera for each of the BTV serotypes available. These assays 
are slow. 
First, time is required to adapt the isolated virus to grow in cell culture; this can take several weeks. Once this 
has been done, a week is required to carry out the test. 
• Serum neutralisation test is a serotype-specific test used to differentiate between antibodies produced 
against different BTV serotypes. The sera to be tested are each reacted separately with a constant 
amount of BTV of each serotype, after which the amount of neutralisation of the virus, compared to 
virus not treated with serum, is measured by infection of mammalian cell cultures. This test is highly 
specific and sensitive; it does not cross-react with other Orbivirus. However, it is time-consuming, and 
uses expensive reagents. If two or more serotypes of BTV are involved in an infection, interpretation of 
results can be difficult as sheep can develop a broad, heterotypic antibody response against multiple 
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serotypes of BTV following infection with more than one serotype. SNTs require the availability of 
reference strains of BTV of all serotypes, are time consuming and labour intensive, therefore are not 
widely used. 
 
Serological tests (to detect BTV antibodies) 
• Complement fixation test (CFT) - largely replaced by the AGID test. 
• Agar gel immunodiffusion test (AGID) serves as an alternative test for international trade. It is simple to 
perform and the antigen used is relatively easy to generate. However, its lack of specificity due to 
detection of other Orbiviruses, including those in the EHD group can render it less usable and AGID 
positive sera may have to be re-tested using a B serogroup specific assay. Those disadvantages have led 
to this test being largely superseded by the competitive ELISA (c-ELISA). 
• Competitive enzyme-linked immunosorbent assay (ELISA). A prescribed test for international trade. BT 
competitive or blocking ELISA was developed to measure BTV-specific antibody without detecting cross- 
reacting antibody to other Orbiviruses; its specificity depends on using one of a number of BT 
serogroup- reactive MAbs. The Indirect ELISA has been shown to be reliable and useful for surveillance 
purposes for bulk milk samples. Both the indirect and competitive ELISA are good tests for rapid 
diagnosis. These have high sensitivity and specificity. Serogroup-specific ELISAs primarily identify 
antibodies to VP7, which is highly conserved across the known BTV serotypes. Competitive ELISA has 
higher sensitivity than indirect ELISA and has been extensively validated in the field. It is a prescribed 
test for international trade. The 50% inhibition value established for sheep and cattle sera also appears 
to be applicable for wild ruminants. Standard cELISA does not distinguish between natural infection and 
animals vaccinated with live attenuated vaccine. However, it can be used to detect the presence of 
circulating virus (even in the absence of clinical disease) by testing young or otherwise unvaccinated 
individuals. An indirect ELISA has been developed and used with both individual and bulk milk samples, 
but should be validated for the relevant serotype(s) before use. An indirect ELISA has been developed to 
antibodies against NS3. This could be used in DIVA alongside inactivated vaccines, since individuals 
vaccinated with an inactivated vaccine do not develop antibodies against NS3. 
• Haemagglutination inhibition (HI) techniques. Can be used for the detection of BTV type-specific 
antibodies. 
 
Detection of BTV and/or its components. A number of techniques can be used to detect the BTV or some of its 
components. These include i) animal inoculation, ii) cell culture, PCR and immunochemistry techniques.   
• Animal inoculation techniques. Inoculation of susceptible sheep is a sensitive method for detection of 
infective BTV. Inoculation of chicken egg embryos has been a standard method for isolation of BTV for 
some time. Intracerebral inoculation into suckling mice (2-3 days old) has been used. 
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• Cell culture techniques. Mammalian cell lines (e.g. Vero cells, BHK-21 cells) cell cultures can be used for 
isolation of BTV and similarly insect cells such as Aedes albopictus clone C6/36; however, cell cultures 
were reported as less sensitive for detection than are embryonated chicken eggs. 
• Reverse transcription-polymerase chain reaction (RT-PCR) can be used as a sensitive test for the 
presence of BTV RNA in clinical samples and in cell culture. Serogroup-specific RT-PCR targets RNA 
segments which are highly conserved within the BTV but different from other orbiviruses. Serotype 
specific RT-PCR is also possible, by targeting segment 2 of the BTV genome. PCR is highly sensitive, but is 
subject to false- positives from cross-contamination. Real-time RT-PCR is extremely sensitive and it has a 
reduced risk of cross-contamination in the laboratory (single-tube reaction) but its sensitivity means that 
even low-level contamination may produce false-positive results. It is also more expensive than 
conventional RT-PCR. 
• Immunofluorescence (Immunohistochemistry) techniques. They can be used for the detection of BTV 
antigen in cell culture or infected tissues. 
 
Immunity 
After recovery from natural infection, sheep have a solid, life-long immunity to the homologous serotype but 
only partial or no protection against heterologous types. Protective immunity is generally associated with the 
presence of type-specific neutralizing antibodies which may persist for years, but is not associated with the 
group specific antibodies which usually disappear after 6 to 18 months. However, infection or immunization with 
more than one virus type usually results in protection against a wider range of serotypes, even types against 
which no neutralizing antibodies are present. This suggests that cell-mediated immunity plays a role as it is less 
type-specific than is the humoral response [5]. 
   
  
Bluetongue | Monograph 20 












Bluetongue virus infection occurs throughout tropical and temperate regions of the world, coincident with the 
distribution of competent vector Culicoides midges. The global distribution of BTV is limited to a band between 
approximately 50°N and 35°S; however, Culicoides midges, including known BTV-vector competent species, 
occur beyond this global range. Therefore, climate and other environmental factors potentially limit the global 
distribution of BTV, even in the presence of appropriate vectors. The global range of BTV has expanded recently, 
especially in the Northern Hemisphere. 
In 2015, active BTV disease was observed in pockets of southern Europe (Italy and Greece), Northern Africa 
(Tunisia) Southern Africa (South Africa) and south Asia (Afghanistan). New strains (not traditionally reported in 
this countries) were reported in Australia, Portugal, Spain, Morocco and in the United States including Alaska 
(OIE, 2015). In Brazil, BTV was limited to specific zones and the disease was suspected to be present in Canada 
and the southern American countries of Venezuela and Ecuador but this was not confirmed. Figure 4 shows the 




Figure 4:  Global status of Blue tongue during the first half of 2015. 
Source:    OIE.    http://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Countrytimelines 
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Incidence data by country 
There are two main sources of information, OIE and AU-IBAR (which includes only Africa), but data are not 
always similar. 
 
1- Source: OIE. 
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 2 and 3.  Data are 
not always reliable, as many countries do not seem to report, or to be reporting consistently over time.  
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
Similar information but presented in a different manner can be seen in Annex 1. 
Number of cases reported to the OIE by disease and by country: 
- No information, +  Present but quantitative data not known,  ? Disease suspected 
 
Table 2: ASIA – BTV outbreaks notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - 0 0 0 - - - - - - 
India 1,182 154 302 132 73 41 38 5 13 14 - 
Indonesia + + - 0 - - - - - - - 
Myanmar 0 0 0 0 0 0 0 0 0 0 - 
Nepal 0 + 0 0 0 0 0 0 0 0 - 
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Table 3: AFRICA – BTV outbreaks notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso - - - - - - - - - - - 
Ethiopia 0 - - - ? - - 0 0 0 - 
Ivory Coast - - - - - - - - - - - 
Kenya 0 0 0 0 0 0 0 0 0 0 0 
Madagascar 0 0 0 0 0 0 0 0 0 0 - 
Malawi - ? ? ? ? ? ? ? ? - - 
Mali 0 0 - - 0 - - - - - - 
Mozambique 0 0 0 0 0 0 0 0 0 0 - 
Rwanda - - - 0 - - - - - - - 
Senegal 0 - 0 0 0 - - - - - - 
South Africa 21 32 6 50 104 15 >62 23 31 86 - 
Tanzania - - - - - - - - - - - 
Uganda 0 0 0 0 +? +? +? +? +? +? +? 




2- Source: AU-IBAR. 
Number of outbreaks per year as reported to AU-IBAR and published in the Pan African Animal Resources 
Yearbook. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=). Table 4 
shows the number of BTV outbreaks reported to AU-IBAR from 2000 – 2005, and table 5 from 2006-2015. Table 
6 shows the number of BTV outbreaks in LVIF countries of interested between 2005 and 2015. 
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Table 4: BTV outbreaks in African countries for the period 2000 - 2005, as reported to AU-IBAR. 
 
Country 2000 2001 2002 2003 2004 2005 
South Africa 98 23 75 64 31 23 
Namibia 4 2 1 0 1 0 
Uganda * * 2 1 0 0 
Lesotho 0 0 0 0 0 3 
TOTAL 102 25 78 65 32 26 
 
* = Data Not Available 
 
Table 5: Number of BTV outbreaks in African countries for the period 2006 – 2015, as reported to AU-IBAR. 
 
Country 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Algeria 28   16 48 12     
Botswana 1  1      1  
Namibia 1   7 6 2 1 1   
Kenya         1  
Lesotho 5 6 2 6 9 11 10 7 9  
Tunisia 4 16  5 8 99 4 2   
South 
Africa 
30 1 50 3 15 41 20  83  
Uganda           
Comoros   3 NS       
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Table 6: Number of BTV outbreaks per year as reported to AU-IBAR and published in the Pan African Animal 
Resources YearBook. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso - - - - - - - - - - N/A 
Ethiopia - - - - - - - - - - N/A 
Ivory Coast - - - - - - - - - - N/A 
Kenya - - - - - - - - - 1 N/A 
Madagascar - - - - - - - - - - N/A 
Malawi - - - - - - - - - - N/A 
Mali - - - - - - - - - - N/A 
Mozambique - - - - - - - - - - N/A 
Rwanda - - - - - - - - - - N/A 
Senegal - - - - - - - - - - N/A 
South Africa 23 30 1 50 3 15 41 20 - 83 N/A 
Tanzania - - - - - - - - - - N/A 
Uganda - - - - - - - - - - N/A 




In summary, the bluetongue situation based on the number of outbreaks per year as reported to AU-IBAR and 
published in the Pan African Animal Resources Yearbook, only 3 out of the 14 African LVIF target countries 
appear to have reported the disease between 2000 and 2014; these were Uganda in 2002 & 2003, Kenya in 2014 
and South Africa virtually throughout the entire period under review except in 2013. 
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Prevalence data by country 
• Sources: PubMed, and internet engine searches (English and French when applicable). 
• Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference. 
• Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted. If a review paper included some 
references, the source of the review is mentioned. 
 
Table 7: Number of BTV outbreaks per year as reported to AU-IBAR and published in the Pan African Animal 
Resources YearBook. 
 
Region/Country Apparent Prevalence (%) Study Design Time 
Period 
References 




































2013 Siddharta et al, 2013 
India 
(Uttar Pradesh) 
28.6 91 sheep and 
goats 
2012 Bitew et al, 2013 
India 
(Andhra Pradesh) 
60.6 Sheep: 1,299 2005-2009 Sairaju et al, 2013 
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47 Goats  De et al, 2007 
India 
(Kerala) 
5.1 Sheep and 
goats: 1,010 
2005 Ravishankar et al, 2005 
Indonesia Last reported to OIE in 
2006. 
  No recent publications 
available 
Myanmar No reported to the OIE, 
at least since 2005. 
  Gard et al, 1995 suspected 
subclinical circulation. No 
recent publications found. 
Nepal Seroprevalence: 25.0% 
sheep and 31.3% goats. 
Estimated that 25% of all 
small ruminants are 
positive and positivity 




survey of 318 
184 sheep and 
134 goats 
2012-2013 Gaire et al, 2014 
Vietnam No reported to OIE, at 
least since 2005. 
  Gard et al, 1995 suspected 
subclinical circulation. No 




Prevalence of the different BTV serotypes in India. The data for BTV-4, 6, 17 and 18 are not shown in figure, as 
they are not available/not known. Source: Chand et al, 2015. Bluetongue in India: A review. Advances in Animal 
and Veterinary Sciences, 2015, 3 (11) 605-612. 
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Table 8: BTV prevalence in LVIV focus countries – AFRICA. 
No recent information (since 2000) has been found for Burkina Faso, Ivory Coast, Malawi, Mali, 










41.17 Goat: 211 
Sheep: 265 











Calves: 0.94 455 calves 2013 Toye et al, 2013 
Madagascar Cattle: 95.9% Random sampling of 4,393 2014 Andriamandimby et al, 
Bluetongue | Monograph 20 








ruminants in 30 districts, 175 
cattle longitudinally followed 




96% 1,260 cattle using commercial C-
ELISA. Isolation of BTV RNA 
observed in 51% of midges in 
autumn and 76% in winter 
2013 Steyn et al., 2015 
Uganda 
(5 regions of 
Karamoja District) 
90% in goats by 
ELISA and 84% 
by BTV RT-PCR 
300 goats. Testing was done by 
commercial ELISA and RT-PCR 
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Economic and Social Impacts at Global 







Although mortality due to bluetongue is often low, it is not uncommon to witness mortality rates approaching 
50% - 100% in susceptible flocks. There are also losses due to morbidity and the need to provide care for the sick 
animals. Costs associated with morbidity of sick animals include weight loss, reduced milk yield, abortion and 
associated veterinary costs. 
During a BTV-2 epidemic in Italy in 2000-2001, approximately 263,000 diseased sheep and goats were reported 
(18% morbidity) and 48,000 sheep and goats died (3% mortality). During a second epidemic in 2001-2002, 
approximately 251,000 diseased sheep and goats were reported (18% morbidity) and 73,000 sheep and goats 
died (5% mortality). In 2007, BTV-8 outbreaks occurred on over 20,000 farms in Germany with disease in 
approximately 35,000 cattle, sheep or goats. 
Additional costs for bluetongue come from the required testing for the virus in animals being considered for 
movement. The impact on cattle industries is through the effects of trade barriers. Bluetongue positive cattle 
are not allowed to be moved from outbreak areas because of the prolonged viremias. Cattle are capable of 
infecting Culicoides and spreading the virus for as long as a month after infection. 
In 2007, a BTV-8 outbreak in France was estimated to cost $1.4 billion. Losses were largely due to the inability to 
trade cattle, a very substantial industry in France, on the international market. In 2007 a BTV-8 outbreak in the 
Netherlands cost approximately $85 million. The southern regions of the U. S. have been endemic for certain 
BTV serotypes for many years though animal disease has been rare. Nevertheless, the impact on the U. S. has 
been losses due to restrictions on the international cattle trade in animals and animal products including semen 
and embryos to regions considered bluetongue-free like some countries in the European Union. The U. S. losses 
in trade and associated testing of cattle for BTV status has been estimated at $130 million annually 
(www.cabi.org/isc/datasheet/). 
In regard to the LVIF target 20 countries, the economic and socio impact of bluetongue are most felt in India and 
South Africa where seasonal occurrence of the disease persists, and numbers of outbreaks are reported to the 
OIE. It is difficult to make definitive statements on the impact of bluetongue on the remaining LVIF target 
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countries, because in some cases it might be poor differential diagnosis that BT could have been mistaken for 
one of the other similar haemorrhagic diseases. 
For most of the 14 target countries for the LIVF in Africa, BT economic impact in comparison to currently other 
prevalent major livestock diseases may not be so obvious. However, of the target countries probably South 
Africa is the most economically affected by bluetongue. For the other countries, its impact socially and 
economically is probably masked by diseases such as FMD, CBPP, PPR and tick-borne diseases. 
 
Analysis by the World Bank 
The World Livestock Disease Atlas – a quantitative analysis of global animal health data [18], published by the 
World Bank (with cooperation of OIE and FAO) in 2011, is an attempt to understand which livestock diseases 
cause the heaviest losses, which countries suffers the worst disease-related losses and which livestock species 
are most affected. http://www- 
wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2012/02/17/000356161_2012021703084
1/Rendered/PDF/668590WP00PUBL00Livestock0Atlas0web.pdf  
The World Livestock Disease Atlas bases its analysis on the Livestock Units (LSU). Each species has a LSU value, 
and the losses of LSU have been given a value.   See Figure 5. For more information on the methodology 
description, please refer to the World Bank Atlas itself (pages 6 & 7). BT is one of the top 10 diseases causing 
losses for small ruminants, as shown in Figure 6. However, looking at the data in detail, there are few data from 
sub-Saharan Africa and Asia. Their analysis shows that India and South Africa belonged to the bluetongue most 
affected countries globally, and as a result of BT they each were assessed to be losing 34 and 25 LSUs 





Figure 5:   Livestock Units. Source: World Livestock Disease Atlas – The World Bank, 2011 [18]. 
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Figure 6: Top 10 diseases in terms of LSU losses for cattle, buffalo, and sheep & goats. Source: World 




Figure 7: BT most affected countries and LSU lost for the period 2006-2009. Source: World Livestock Disease 
Atlas – The World Bank, 2011 [18]. 
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No specific treatment is available for BT. Treatment of BT-affected ruminants is often unrewarding and 




The most effective way to control BTV is by employing measures that prevent the introduction of BTV to a 
susceptible herd. All efforts to control BTV generally fall into measures to prevent infection in disease free zones 
(see section c below) and a different set of distinct measures for areas that are already affected and where the 
focus is on avoiding further transmission within the affected area (see section d below). 
 
Prevention of new BTV infections in BTV-free areas 
Prevention of entry of bluetongue into a bluetongue-free area hinges on: 
i) serological surveillance for BT 
ii) vector surveillance and control followed by definition of bluetongue-free zones 
Guidelines and recommendations for ensuring BTV-free zones are presented by the OIE 
(http://www.oie.int/doc/ged/D12367.PDF). There are sanitary measures, and mechanical and biological 
control methods. The most important sanitary measure to avoid introduction of BTV in a free country is testing 
and safe importation of live animals including semen and embryos. The OIE has developed clear guidelines on 
the type of diagnostic tests that should be carried out prior to importation of animals or animal materials from 
BTV endemic areas. Additional measures include vector surveillance and control. This approach involves use of 
use of insecticides in the animal premises and in the areas where these insects live, insect repellents onto 
animals, mosquito nets, etc. especially in areas that are under threat of infection. 
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Control of BTV in Endemic Areas 
For areas that are already affected, the approaches used are: 
iii) quarantine of BT affected animal populations 
iv) vaccination of potentially susceptible populations with BT vaccines 
v) vector surveillance and control. 
Measures to control the disease and the spread of infection include prompt reporting of BT outbreaks and 
implementation of appropriate serological and entomological surveillance. Vaccination of naïve animals is 
critical. 
Simple husbandry changes and practical midge control measures may help break the BT livestock infection cycle. 
Housing livestock during times of maximum midge activity (from dusk to dawn) may lead to significantly reduced 
biting rates. Similarly, protecting livestock shelters with fine mesh netting or coarser material impregnated with 
insecticide will reduce contact with the midges. The Culicoides midges that carry the virus usually breed on 
animal dung and moist soils, either bare or covered in short grass. Identifying breeding grounds and breaking the 
breeding cycle will significantly reduce the local midge population [19]. Turning off taps, mending leaks and filling 
in or draining damp areas will also help dry up breeding sites. Control by trapping midges and removing their 
breeding grounds may reduce vector numbers. Dung heaps or slurry pits should be covered or removed, and 
their perimeters (where most larvae are found) regularly scraped. If cattle are treated with Ivermectin, 
Culicoides feeding on the cattle have high mortality and faeces passed for the following 28 days may be 
larvicidal. 
Ultimately, effective control of BT can only be achieved through restriction of quarantine of infected animals and 
the use of mass vaccination in areas under threat of outbreaks. 
 
Vaccination as a method for control of Bluetongue 
Mass vaccination has successfully been used to control BT. The vaccines (see Section 6) used against BT must 
correspond to the serotype under circulation. For vaccination to be effective, the experience of vaccination 
against serotype BTV-4 in the Balearic Islands of Spain, has demonstrated that coverage must attain 80% of 
animals over a prolonged period of time to successfully stop an outbreak 
(http://www.discontools.eu/Diseases/Detail/38). 
 
Vaccination with inactivated vaccines in the recent northern European outbreaks has been extremely successful, 
for example the UK completely prevented re-emergence of the BTV outbreak in 2008. The number of infected 
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farms in France was also reduced from 29,000 to <100 between 2008 and 2009. This was achieved through high 
levels of vaccine coverage (>80%) using  a compulsory vaccination programme.  Similar reductions in  the 
incidence of disease have been achieved in Holland, Germany, Belgium and the UK through vaccination. 
Different vaccines have been applied since the disease started in the EU. During the outbreaks of 2000-2005, 
sheep in France were vaccinated with live attenuated vaccines against serotypes 2, 4 and 16; and sheep in Spain 
were vaccinated against serotypes 2 and 4. In Italy from 2002-2005 domestic ruminants (cattle, goats and sheep) 
were vaccinated with live attenuated vaccine against serotypes 2, 4, 9 and 16. 
It is important to note that the use of vaccines to control BTV can only be successful with cross-border 
agreements and uniform international or regional policies, as has been demonstrated in Europe under the joint 
action plan against BTV during the outbreaks of the last decade (see  
http://ec.europa.eu/food/animal/diseases/controlmeasures/bluetongue_en.htm). It is difficult to foresee 
how the same approach can succeed in developing countries with the existing weak legislative and policy 
frameworks against livestock diseases. 
The use of these live vaccines does have some drawbacks. They may revert to virulence or may already be 
virulent in naïve populations; they may induce abortion when given to pregnant females, they cause viraemia, 
can circulate in the field in Culicoides midge populations and the vaccine virus may undergo reassortment with 
circulating field strains of another serotype or topotype. However, despite these drawbacks, live attenuated 
vaccines have been used successfully for many years to protect animals and control the disease in endemic areas 
such as Southern Africa, and in some circumstances (Balearic Islands) eradicating the infection. 
 
Disease situation and government policies by country 
Tables 9 and 10 below have been completed with the information received from the questionnaires sent to the 
Director Generals and Directors of the Veterinary Services for BT.  
Table 9 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation. Table 10 refers to the vaccination situation. 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination of 
information to those who need to know so that action can be taken. 
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country for 
the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that country, 
or within a zone or compartment of that country. 
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Table 9: Official status, official programs and treatment for BT in the countries of interest. 
Information provided by the questionnaire sent to the DG/DVS as part of this monograph. Replies were not 




















Bangladesh N/A - - - - 
Myanmar No No No No Yes 
Nepal Yes Yes, passive No No No 




Yes Yes, passive but active if 
outbreak 
No - - 
Kenya Yes Yes, passive No No No 
Malawi Yes Yes, passive Yes N/A N/A 
Mali N/A N/A N/A N/A N/A 
Rwanda - - - - - 
Tanzania Yes Yes, passive No No No 
Uganda Yes No No N/A N/A 
Zambia Yes Yes, passive No No No 
 
- Left blank in the questionnaire by the respondent. 
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Table 10: Vaccination for BT in the countries of interest. 
Information provided by the questionnaire sent to the DG/DVS as part of this monograph. Replies were not 


















(cattle, sheep, goats, 
pigs, poultry) 
ASIA 
Bangladesh - - - - 
Myanmar No - - - 
Nepal No N/A N/A N/A 
Vietnam No - - - 
AFRICA 
Ivory Coast No - - - 
Kenya No Combination Both Cattle, sheep, goats 
Malawi No N/A N/A N/A 
Mali N/A N/A N/A N/A 
Rwanda - - - - 
Tanzania No Not done, disease has never been reported 
Uganda No Never vaccinated 
Zambia No N/A N/A N/A 
 
- Left blank in the questionnaire by the respondent. 
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Broadly, the bluetongue vaccines fall into three groups, namely i) Live modified/attenuated, ii) Inactivated 
(killed) vaccines, and iii) Recombinant vaccines. Live attenuated vaccines and inactivated vaccines may be 
monovalent or polyvalent. Presently, there are no recombinant BTV vaccines that are licensed or on the market. 
There are no vaccines (live or inactivated) that allow the differentiation between vaccinated and infected 
animals (DIVA). 
 
Live attenuated BTV vaccines 
Live attenuated vaccines are developed by the multiple passage of virulent strains in culture or in embryonated 
chicken eggs (ECE). Production time is estimated in about 8 – 10 weeks, including production and quality control 
[20]. These vaccines can be highly effective in epidemic situations where only one serotype of BT virus is involved. 
They generate protective immunity after a single inoculation and they have proven effective in preventing 
clinical BT disease. 
In endemic areas where multiple serotypes exist, the situation is more complicated as it requires multivalent 
vaccines because protection from BTV vaccines is serotype specific. Unfortunately, multivalent vaccines have 
problems resulting from interference between virus strains, varying immunogenicity and growth rates between 
virus strains, as well as variations in the immune responses of individual animals to the components of such 
vaccines [5]. In addition, concerns have been raised about the drawbacks of using live attenuated BTV vaccines. 
These include under-attenuation, although impact may vary with sheep of different breeds, potential depressed 
milk production in lactating sheep and abortion/embryonic death and teratogenesis in offspring if used in 
pregnant animals. The risk is increased when the live vaccines are injected during the first third of pregnancy. 
Other concerns include the presence of vaccine virus in semen secretions of bulls and rams, and the possibility 
that vaccine virus will infect vectors and establish in the environment. Furthermore, there are fears of inducing 
recombinant progeny virus, with novel genetic and biological properties following re-assortment of genes from 
wild and vaccine virus in the vaccinated animal or the vector. 
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Several monovalent live attenuated vaccine combinations have been used in the field with side effects evident 
mainly in sheep. In this species, following vaccination, some animals developed fever, oedema in the facial 
region and lameness. In most cases these symptoms appeared during the second week of vaccination and 
disappeared in 7-10 days. Symptoms were generally more critical when animals suffered from other concurrent 
diseases. More severe clinical signs involving a higher number of sheep also occurred when BTV-16 were 
included in the vaccine combination. Because of these drawbacks, the use of BTV-16 monovalent vaccine was 
banned from the BTV vaccination campaigns in Europe. 
These concerns have been considered serious enough that some authorities prohibit the use of live attenuated 
vaccines against BTV. Nonetheless, live attenuated BT vaccines have wide usage in South Africa, Italy, Morocco, 
Spain and France, and to a smaller extent in the USA. It must be noted that the attenuation is not characterized. 
 
Inactivated BTV Vaccines 
To overcome some of the drawbacks of live vaccines, inactivated vaccines have been developed although their 
main disadvantage is poor immunogenicity, so they usually require repeated immunization. Other potential 
disadvantages include increased costs due to the large amount of antigen required, and there are some 
concerns over the reliability of inactivation for each vaccine batch [as quoted in [21]]. 
Inactivated BTV vaccines are produced in large-scale suspension cell systems, in cell lines that are free from 
contamination and which are adapted for large scale commercial use. After growth, inactivation is carried by the 
use of chemicals like binary ethyleneimine (BEI) or other manufacturer specific methods. Typically, inactivation 
should not interfere with immunogenicity of the inactivated virus, and adjuvants are added. The production time 
frame for inactivated vaccines is estimated to be 6-8 months depending on the vaccine needs. 
(http://www.oie.int/fileadmin/Home/fr/Health_standards/tahm/2.01.03_BLUETONGUE.pdf). 
Inactivated vaccines are generally safe although on a few occasions, local reactions occurred. Of particular 
interest are the cases of anaphylactic shock reported in areas where live vaccination was previously applied [20]. 
In the BT review done by the EU Scientific Panel on animal health and welfare [20], they noted that when BT 
inactivated vaccines where administered in two doses, all BTV inactivated vaccines were able to fully protect the 
animals from clinical signs and viraemia for a long period. Conversely, a single shot of a BTV-4 inactivated 
vaccine gave only partial reduction of viraemia in cattle when challenged 7 months after vaccination. It has to be 
mentioned that each of these studies on the efficacy of the inactivated vaccine followed its own challenge 
protocol and used different age, breed and number of animals, dose and type of challenge, route of inoculation. 
Differences were also on the methods employed to evaluate the efficacy of the vaccine. To detect viraemia, 
some trials utilized quantitative RT-PCR, some others classical virus isolation. The immunogenicity was assessed 
by serum neutralisazion (SN) assay and discrepancy existed also on the way the SN test was interpreted. Some 
considered a serum as positive for BT when titers were ≥ 1/4, others when they were ≥ 1/10. 
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Recombinant BTV vaccines 
A number of approaches have been used to develop recombinant or sub-unit BTV vaccines and are covered 
under Section 8, describing current research for BTV vaccines. 
 
Commercial vaccines manufactured in Africa and Asia  
 
As indicated above, bluetongue virus is characterised by several serotypes that do not necessarily cross-protect. 
Consequently, there are several bluetongue vaccines to take into account the different BTV serotypes. 
In the literature reviewed, the 8 monovalent BT vaccines  comprised i) BT-1, ii) BT-2, iii) BT-4, iv) BT-8, v) BT-9, vi) 
BT-10, vii) BT-11,and viii) BT-17 while the 4 polyvalent BT  vaccines were i) BT-1,4, ii) BT-1,8, iii) BT-2,4, and iv) 
the South African polyvalent that consists of (bottle A - BT-1, 4, 6, 12, 14; bottle B – BT-3, 8, 9, 10, 11; and bottle 
C – BT-2, 5, 7, 13, 19). 
Below, Tables 11 and 12 list the BT vaccine manufacturers with the information sourced from The Center for 
Food Security and Public health, Iowa State University (www.cfsph.iastate.edu/vaccines/index.php) and Vetvac 
(www.vetvac.org). Inserts of some of the commercial vaccines are included in Annex 2. 
 
Table 11: Manufacturers of BT monovalent vaccines 
 
BTV Serotype Vaccine trade name Vaccine type Manufacturer 
1 BLUVAC® 1 Inactivated CZ Veterinaria S.A., Spain 
1 BTVPUR Alsap™ 1 Inactivated Merial SAS (France) 
1 Syvazul 1 Inactivated SYVA Laboratorios, Spain 
1 Zulvac 1 Bovis Inactivated Zoetis Spain 
1 Zulvac 1 Ovis Inactivated Zoetis Spain 
2 BTVPUR Alsap™ 2  Merial SAS (France) 
4 Freeze Dried Monovalent 
Bluetongue vaccine for sheep 
Live Central Veterinary Control and 
Research Institute, Turkey 
4 BLUEVAC® 4 Inactivated CZ Veterinaria S.A., Spain 
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4 BTVPUR Alsap™ 4 Inactivated Merial SAS (France) 
4 Syvazul 4 Inactivated SYVA Laboratorios, Spain 
8 BLUEVAC® 8  CZ Veterinaria S.A., Spain 
8 BOVILIS® BTV8  MSD Animal Health (Merck) 
8 Syvazul 8  SYVA Laboratorios, Spain 
8 Zulvac 8 Bovis  Zoetis Spain 
8 Zulvac 8 Ovis  Zoetis Spain 
9 BTVPUR Alsap™ 9 Inactivated Merial SAS (France) 
10 Bluetongue vaccine Live Colorado Serum Company, USA 
10 BlueVac-10 Live Poultry Health Laboratories, USA 
11 BlueVac-11 Live Poultry Health Laboratories, USA 
17 BlueVac-17 Live Poultry Health Laboratories, USA 
? Bluetongue vaccine ? Institute of Animal Health and 
Veterinary Biologicals* 
 
NB. All CZ Veterinaria S.A., Spain BT vaccines are “aqueous” while all Merial SAS (France) & Zoetis Spain BT vaccines have 
Aluminium hydroxide, saponin adjuvant but all the SYVA Laboratorios, Spain BT vaccines have oil adjuvant. The rest are 
not adjuvanted. 
* According to the website, it is in experimental stage: http://www.kvafsu.kar.nic.in/IAHVB.htm 
 
Table 12: Manufacturers of BT monovalent vaccines 
 
BTV Serotype Vaccine trade name Vaccine type Manufacturer 
Serotype 1, 4 BLUEVAC® 1+4 Inactivated CZ Veterinaria S.A., Spain 
Serotype 1, 8 BLUEVAC® 1+8 Inactivated CZ Veterinaria S.A., Spain 
Serotype 1, 8 BTVPUR Alsap™ 1-8 Inactivated Merial SAS, France 
Serotype 1, 8 Syvazul 1+8 Inactivated SYVA Laboratorios, Spain 
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Serotype 2, 4 BTVPUR Alsap™ 2-4 Inactivated Merial SAS, France 
1, 2, 3, 4, 8, 12 and 13 Bluvax TM Live KEVEVAPI, Kenya 
Polyvalent as below A 
[1, 4, 6, 12 and 14] 
B [3, 8, 9, 10 and 11] 
C [2, 5, 7, 13 and 19] 
Bluetongue Vaccine Live Onderstepoort Biological Products 
Ltd, South Africa 




With respect to the 20 target countries for the Livestock Vaccine Innovation Fund, it is only South Africa 
(Onderstepoort Biological Products Ltd), Kenya (KEVEVAPI) and India (IIL) that manufacture vaccines against 
bluetongue. For the polyvalent vaccine used in South Africa, the three bottles of vaccine, each containing five 
serotypes of BTV, should be given in the correct order (A, B then C), at intervals of three weeks. Sheep should be 
vaccinated with live attenuated vaccines yearly. It is noted that in most of the LVIF target countries in Africa, the 
most likely source of vaccine for protection of their domesticated animals is OBP. However, the OBP Bluetongue 
vaccine carries with it the undesirable feature of introducing some BTV serotypes that might not be present in 
the vaccine importing country. The OBP product accompanying leaflet is scanned and included in Annex 2 of this 
monograph. 
In January 2015, Indian researchers and Indian Immunologicals Ltd (IIL) were reported to have launched its 
bluetongue vaccine, named 'Raksha Blu', expected to protect the animals against unspecified five strains of the 
‘bluetongue’ virus prevalent in the country. It was publicised in various media including The Hindu – 
BusinessLine and Pharmabiz.com. Following direct contact with the responsible of the Research & Development 
at ILL, a product vaccine information leaflet was provided and the scanned copy of it is included in Annex 2 of 
the monograph. It is also interesting to note that despite the many BT outbreaks, vaccination did not feature as 
a prominent method of control of the disease in India; this could be probably because they did not have their 
own nationally produced vaccine. The other control measures, which they have adopted, particularly since 2008 
seem to be quite effective as evidenced by the sharp decline in the number of outbreaks. On the other hand, 
South Africa was clearly using vaccination as one of the main control measures of BT.  
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail. 
Other manufacturers, particularly the European ones, are likely to supply West and North Africa and probably 
some of Asian countries where there are no BT manufacturing facilities. 
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Commercial vaccines imported into Africa and Asia 
 
Based on the questionnaire sent to the Directors of Veterinary Services office and regulators of the countries of 
interest, only Zambia seems to have been importing the vaccine (see Table 13). Note that replies were not 
received from India, Indonesia, Burkina Faso, Ethiopia, Madagascar, Mozambique, Senegal and South Africa. 
 
Table 13: Commercial BT vaccines imported into the countries of interest 
 

















Zambia   Ireland 0 10,000 0 - 
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers. 
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders. 
While efforts have been made to encompass them, the TPP showed in Table 14 below, should be considered a 
proposal, a live document subject to improvements. 
Table 14: Target Product Profile (TPP) BT vaccine – Proposal: 
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen Immunogen with protective antigens 
against a specific serotype of BTV. 
There are some polyvalent vaccines, 
but none protects against all 
serotypes. 
Immunogen with protective antigens 
against all 27 serotypes of BTV 
2 Indication for use For active immunization of sheep, 
goat & cattle to prevent incidence of 
BT 
For active immunization of ruminants, 
to prevent infection with BTV 
3 Recommended species Sheep, cattle, goats All susceptible domesticated and wild 
ruminants 
4 Recommended dose 1-2 ml SC 1 ml 
5 Pharmaceutical form Reconstituted injectable solution Ready to use solution 
6 Route of administration Subcutaneous Either subcutaneous or intramuscular 
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7 Regimen - primary 
vaccination 
Primary vaccination - some have to 
be repeated with either same or 
different serotypes 3 weeks apart 
Preferably single inoculation 
8 Regimen - booster Annual injection is recommended Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protects against specific serotypes 
used in vaccination 
Protects against all field BTV serotypes 
10 Recommended age at first 
vaccination 
1 month old in naïve sheep & cattle; 
2.5 to 3 months in young born to 
immune sheep/cattle 
Preferably within first 2 months of age 
11 Onset of immunity 3 weeks post vaccination One week following vaccination 
12 Duration of immunity Generally about 1 year Lifelong 
13 Expected efficacy Prevents viraemia and reduce clinical 
signs 
Prevent BT clinical disease & BTV 
transmission in all vaccinated animals 
14 Expected safety Inoculation may be followed by a 
small local swelling at the injection 
site for a short period (at most 14 
days). A transient increase in body 
temperature may also occur. 
Not cause any clinical disease; 
incapable of replicating in the 
inoculated host; no reversion to 
virulence; no re-assortment with field 
strains 
15 Withdrawal period Depending on manufacturer could be 
0 to 21 days 
None 
16 Special requirements for 
animals 
Only vaccinate healthy animals. Vaccinate all animals 
17 Special requirements for 
persons 
None None 
18 Package size 50, 80, 100, 250 ml Multiple pack size from 10 doses 
19 Price to end user   
20 Storage condition and 
shelf-life as packaged for 
sale 
2 to 8 °C, 12 months 20° C for at least 12 months 
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21 In-use stability Within few hours of 
Puncturing the vial 
Preferably 8 to 12 hours 
22 Other: DIVA capabilities No Yes 
23 Other: reassortment 
possibility 
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated. 
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph. If any of these projects were to be pursued, a detailed peer review taking into 
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ANNEX 1: Additional data on disease presence and 
incidence 
 
Reports to OIE on BT: 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals. 
BT in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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BT in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal
 
BT in Eastern Africa: Ethiopia, Kenya, Rwanda, Tanzania and Uganda
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ANNEX 2: Labels from different BT commercially 
available vaccines 
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